After loss of millions: Biontech is spreading spots

Biontech has clearly slipped into the loss zone on the way to developing cancer medication and now wants to reduce jobs. The Mainz company known for its Corona vaccine announced that the reason for the red figures was the high investments, especially in expensive clinical studies.

In addition to reducing areas, job relocations are also planned. The headquarters of Mainz should be strengthened. In the line, a net loss of around 700 million euros stood in 2024. This continues the development that had started when business with the Covid 19 vaccine leaked off. In 2022, the profit was still around 9.4 billion euros, in 2023 it was only about 930 million. After below, the sales were also possible: after 3.8 billion euros 2023, it was around 2.75 billion in 2024. For the current year, a little less redeems of 1.7 to 2.2 billion euros are expected with further high expenditure for research and development from 2.6 to 2.8 billion euros.2026, the first market approval is to come from the development of cancer therapies on a mRNA basis. Roughly speaking, the patient’s immune system is to be helped to identify and destroy cancer cells based on certain characteristics. 2026 wants to get Biontech a first market approval. Mainz is comparatively far in developing preparations against bladder cancer and for the treatment of colon cancer. In the latter, important new studies are expected for the end of this or beginning of next year. Biontech puts great hope in the treatment of cancer in late stages on an active ingredient candidate named BNT327. Among other things, it is intended to counteract the effects of tumors that suppress the body’s immune system. Biontech had secured the worldwide rights to the candidate for active ingredients with the takeover of the Chinese company Biothine. For about three years by the end of 2027, it should be 950 to 1350 full -time equivalents in Europe and North America. At the end of 2024, Biontech had around 7,200 employees worldwide, because of the lower demand for covid vaccine, for example, the Marburg location will be affected, where 250 to 350 is to be eliminated from 670 full-time equivalents. In Idar-Oberstein, which counts 450 full-time positions, up to 150 are to be dismantled. Personnel is to be set up in other areas, and there is talk of 800 to 1200 jobs. Around 350 alone are to be built at the headquarters in Mainz in the current year alone. Biontech speaks of a clear commitment to Germany.

Credit-Read More

// Function to fetch the latest posts
function fetchLatestPosts() {
const feedUrl = ‘https://newskiosk.pro/feed/’; // Replace with your blog’s RSS feed URL
fetch(feedUrl)
.then(response => response.text())
.then(str => new window.DOMParser().parseFromString(str, “text/xml”))
.then(data => {
const items = Array.from(data.querySelectorAll(“item”));
const latestPostsContainer = document.getElementById(“latest-posts”);
latestPostsContainer.innerHTML = ”; // Clear previous posts

// Shuffle the items array
const shuffledItems = items.sort(() => Math.random() – 0.5);

// Select the first 5 items from the shuffled array
const selectedItems = shuffledItems.slice(0, 5);

// Loop through the selected items and display them
selectedItems.forEach(post => {
const link = post.querySelector(“link”).textContent;
const description = post.querySelector(“description”).textContent;

// Create a new post element
const postElement = document.createElement(“div”);
postElement.classList.add(“latest-post”);
postElement.innerHTML = `

${description} Read more

`;

// Append the new post element to the container
latestPostsContainer.appendChild(postElement);
});
})
.catch(error => console.error(‘Error fetching the latest posts:’, error));
}

// Call the function to fetch and display the latest posts
fetchLatestPosts();